These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12205498)

  • 41. Vouchers for FDA priority reviews.
    Spatz ID
    Health Aff (Millwood); 2006; 25(4):1184; author reply 1184-5. PubMed ID: 16835203
    [No Abstract]   [Full Text] [Related]  

  • 42. Findings halt clinical trials of centoxin.
    Wagner M
    Mod Healthc; 1993 Jan; 23(4):16. PubMed ID: 10123669
    [No Abstract]   [Full Text] [Related]  

  • 43. What's fueling the biotech engine-2007.
    Aggarwal S
    Nat Biotechnol; 2008 Nov; 26(11):1227-33. PubMed ID: 18997759
    [No Abstract]   [Full Text] [Related]  

  • 44. Billion dollar babies--biotech drugs as blockbusters.
    Lawrence S
    Nat Biotechnol; 2007 Apr; 25(4):380-2. PubMed ID: 17420735
    [No Abstract]   [Full Text] [Related]  

  • 45. Biologicals: new horizons in pharmaceutical development.
    Oldham RK
    J Biol Response Mod; 1983; 2(3):199-206. PubMed ID: 6358418
    [No Abstract]   [Full Text] [Related]  

  • 46. Genmab signs cancer deal with Janssen.
    Tung J
    Bioanalysis; 2012 Oct; 4(19):2327. PubMed ID: 23251918
    [No Abstract]   [Full Text] [Related]  

  • 47. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 48. Nutraceuticals: miracle or meme?
    Ridinger MH
    Clin Pharmacol Ther; 2007 Oct; 82(4):352-6. PubMed ID: 17851571
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correcting Hatch-Waxman.
    Fernandes M
    Health Aff (Millwood); 2008; 27(3):902-3; author reply 903. PubMed ID: 18475000
    [No Abstract]   [Full Text] [Related]  

  • 50. The biotech drug market.
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
    [No Abstract]   [Full Text] [Related]  

  • 51. A merger too far?
    Wadman M
    Nature; 2007 Mar; 446(7131):15. PubMed ID: 17330017
    [No Abstract]   [Full Text] [Related]  

  • 52. New-wave diagnostics.
    Baker M
    Nat Biotechnol; 2006 Aug; 24(8):931-8. PubMed ID: 16900134
    [No Abstract]   [Full Text] [Related]  

  • 53. Big Pharma's small wonder.
    Fry E
    Fortune; 2014 Jun; 169(8):178-84, 186. PubMed ID: 25211849
    [No Abstract]   [Full Text] [Related]  

  • 54. New relief for gout.
    Adams JU
    Nat Biotechnol; 2009 Apr; 27(4):309-11. PubMed ID: 19352359
    [No Abstract]   [Full Text] [Related]  

  • 55. US drug approval ignores science's subtleties, experts say.
    Waltz E
    Nat Med; 2006 Apr; 12(4):373. PubMed ID: 16598269
    [No Abstract]   [Full Text] [Related]  

  • 56. A rollercoaster ride.
    Jacobs T
    Nat Biotechnol; 2006 Mar; 24(3):284. PubMed ID: 16525390
    [No Abstract]   [Full Text] [Related]  

  • 57. Will this experiment work?
    Kadlec D
    Time; 2003 Jul; 162(1):80-1. PubMed ID: 14584341
    [No Abstract]   [Full Text] [Related]  

  • 58. Abbott Laboratories backlists Thailand from new AIDS/HIV drugs.
    Monash Bioeth Rev; 2007; 26(1-2):11. PubMed ID: 17867317
    [No Abstract]   [Full Text] [Related]  

  • 59. Beyond the lab in biotech. With so many drugs in trial, new jobs are opening up.
    Carmichael M
    Newsweek; 2002 Sep; 140(13):53. PubMed ID: 12375414
    [No Abstract]   [Full Text] [Related]  

  • 60. HHS: POUFA reauthorization good for Americans.
    FDA Consum; 2002; 36(5):5. PubMed ID: 12412536
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.